CA2623018A1 - Compositions pharmaceutiques de telmisartan - Google Patents

Compositions pharmaceutiques de telmisartan Download PDF

Info

Publication number: CA2623018A1
Authority: CA; Canada
Prior art keywords: pharmaceutical composition; telmisartan; amount; composition according; diluent
Prior art date: 2005-11-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002623018A

Other languages

English (en)

Inventor

Gershon Kolatkar

Erela Zisman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teva Pharmaceutical Industries Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-22

Filing date

2005-11-22

Publication date

2007-05-31

2005-11-22 Application filed by Individual filed Critical Individual

2007-05-31 Publication of CA2623018A1 publication Critical patent/CA2623018A1/fr

Status Abandoned legal-status Critical Current

Links

RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title claims abstract description 172
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 118
239000005537 C09CA07 - Telmisartan Substances 0.000 title claims abstract description 94
229960005187 telmisartan Drugs 0.000 title claims abstract description 90
239000003085 diluting agent Substances 0.000 claims abstract description 71
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 71
239000000203 mixture Substances 0.000 claims abstract description 68
239000003795 chemical substances by application Substances 0.000 claims abstract description 26
239000004094 surface-active agent Substances 0.000 claims abstract description 24
-1 telmisartan compound Chemical class 0.000 claims abstract description 21
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 20
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 20
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 20
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 20
238000000034 method Methods 0.000 claims description 42
239000008187 granular material Substances 0.000 claims description 32
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 25
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 23
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 23
239000000945 filler Substances 0.000 claims description 20
239000007884 disintegrant Substances 0.000 claims description 19
239000011230 binding agent Substances 0.000 claims description 16
238000005469 granulation Methods 0.000 claims description 16
230000003179 granulation Effects 0.000 claims description 16
239000000314 lubricant Substances 0.000 claims description 16
229920003109 sodium starch glycolate Polymers 0.000 claims description 16
239000008109 sodium starch glycolate Substances 0.000 claims description 16
229940079832 sodium starch glycolate Drugs 0.000 claims description 16
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 15
239000000600 sorbitol Substances 0.000 claims description 15
235000010356 sorbitol Nutrition 0.000 claims description 15
239000002552 dosage form Substances 0.000 claims description 14
229940069328 povidone Drugs 0.000 claims description 13
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 12
235000019359 magnesium stearate Nutrition 0.000 claims description 12
229960003194 meglumine Drugs 0.000 claims description 12
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 10
238000002156 mixing Methods 0.000 claims description 10
229920001993 poloxamer 188 Polymers 0.000 claims description 10
229940044519 poloxamer 188 Drugs 0.000 claims description 10
239000008240 homogeneous mixture Substances 0.000 claims description 8
239000000725 suspension Substances 0.000 claims description 8
230000007935 neutral effect Effects 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
206010020772 Hypertension Diseases 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 5
239000008213 purified water Substances 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
239000004359 castor oil Substances 0.000 claims description 3
235000019438 castor oil Nutrition 0.000 claims description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
238000004513 sizing Methods 0.000 claims description 3
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 2
150000001413 amino acids Chemical class 0.000 claims description 2
150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
150000004679 hydroxides Chemical class 0.000 claims description 2
235000021317 phosphate Nutrition 0.000 claims description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
229920001983 poloxamer Polymers 0.000 claims description 2
239000008389 polyethoxylated castor oil Substances 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
229940068965 polysorbates Drugs 0.000 claims description 2
239000003826 tablet Substances 0.000 description 34
239000000546 pharmaceutical excipient Substances 0.000 description 16
238000009472 formulation Methods 0.000 description 14
239000002775 capsule Substances 0.000 description 9
239000007864 aqueous solution Substances 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000007916 tablet composition Substances 0.000 description 6
229920003084 Avicel® PH-102 Polymers 0.000 description 5
238000007907 direct compression Methods 0.000 description 5
238000007922 dissolution test Methods 0.000 description 5
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229940101564 micardis Drugs 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
229940033134 talc Drugs 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
238000005550 wet granulation Methods 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
239000008101 lactose Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
230000036515 potency Effects 0.000 description 3
229920003124 powdered cellulose Polymers 0.000 description 3
235000019814 powdered cellulose Nutrition 0.000 description 3
235000002639 sodium chloride Nutrition 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
229940032147 starch Drugs 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
239000005995 Aluminium silicate Substances 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
239000004375 Dextrin Substances 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
235000012211 aluminium silicate Nutrition 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000005555 hypertensive agent Substances 0.000 description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
102000008873 Angiotensin II receptor Human genes 0.000 description 1
108050000824 Angiotensin II receptor Proteins 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
206010051113 Arterial restenosis Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
229920003072 Plasdone™ povidone Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000012615 aggregate Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229940078456 calcium stearate Drugs 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
201000009101 diabetic angiopathy Diseases 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
235000012245 magnesium oxide Nutrition 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229960000540 polacrilin potassium Drugs 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000008719 thickening Effects 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
208000026533 urinary bladder disease Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
229940057977 zinc stearate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA002623018A 2005-11-22 2005-11-22 Compositions pharmaceutiques de telmisartan Abandoned CA2623018A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2005/042700 WO2007061415A1 (fr)	2005-11-22	2005-11-22	Compositions pharmaceutiques de telmisartan

Publications (1)

Publication Number	Publication Date
CA2623018A1 true CA2623018A1 (fr)	2007-05-31

Family

ID=36645450

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002623018A Abandoned CA2623018A1 (fr)	2005-11-22	2005-11-22	Compositions pharmaceutiques de telmisartan

Country Status (6)

Country	Link
JP (1)	JP2009515956A (fr)
CN (1)	CN101312714A (fr)
AU (1)	AU2005338461A1 (fr)
CA (1)	CA2623018A1 (fr)
IL (1)	IL189614A0 (fr)
WO (1)	WO2007061415A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9427402B2 (en)	2010-09-30	2016-08-30	Shionogi & Co. Ltd.	Preparation for improving solubility of poorly soluble drug

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8637078B2 (en) *	2005-11-24	2014-01-28	Boehringer Ingelheim International Gmbh	Bilayer tablet comprising telmisartan and diuretic
JP2010535212A (ja) *	2007-08-01	2010-11-18	テバファーマシューティカルインダストリーズリミティド	改良されたカンデサルタンの製剤
CZ301070B6 (cs) *	2008-07-31	2009-10-29	Zentiva, A. S.	Telmisartan tablety
CZ2008740A3 (cs) *	2008-11-24	2010-01-06	Zentiva, A.S.	Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
CN102552161B (zh) *	2010-12-28	2016-06-22	上海中西制药有限公司	一种药物固体制剂的制备方法及所得药物固体制剂
CN102532033A (zh) *	2012-02-29	2012-07-04	江西杏林白马药业有限公司	替米沙坦成盐工艺
KR20150111918A (ko) *	2012-12-21	2015-10-06	테바 파마슈티컬 인더스트리즈 리미티드	글라티라머 아세테이트의 경점막 전달
WO2014119767A1 (fr) *	2013-01-31	2014-08-07	沢井製薬株式会社	Comprimé multicouche contenant du telmisartan et de l'hydrochlorothiazide
JP6218664B2 (ja) *	2013-04-04	2017-10-25	沢井製薬株式会社	テルミサルタン含有錠剤
CN104688696B (zh) *	2013-12-04	2017-12-19	长春海悦药业股份有限公司	一种含有坎地沙坦酯的药物组合物
EP2979691A1 (fr) *	2014-07-30	2016-02-03	Boehringer Ingelheim International GmbH	Comprimé à désintégration orale
JP5871294B1 (ja) *	2015-02-27	2016-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	即時放出経口錠剤
WO2019130049A1 (fr)	2017-12-29	2019-07-04	Grünenthal GmbH	Combinaison pharmaceutique comprenant du chlorhydrate de tramadol à libération prolongée et de l'étoricoxib à libération immédiate, et son utilisation pour le traitement de la douleur
CN110934848B (zh) *	2019-12-20	2022-02-15	江西杏林白马药业股份有限公司	一种替米沙坦胶囊及其制备方法
CN115245497A (zh) *	2021-04-26	2022-10-28	武汉伯睿科医药科技有限公司	替米沙坦胶囊及其制备工艺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0215514A (pt) *	2002-01-16	2004-12-21	Boehringer Ingelheim Pharma	Comprimido farmacêutico de bicamada compreendendo telmisartan e um diurético e preparação deste
DE10244681A1 (de) *	2002-09-24	2004-04-08	Boehringer Ingelheim International Gmbh	Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung

2005
- 2005-11-22 CA CA002623018A patent/CA2623018A1/fr not_active Abandoned
- 2005-11-22 JP JP2008541140A patent/JP2009515956A/ja active Pending
- 2005-11-22 CN CNA2005800521169A patent/CN101312714A/zh active Pending
- 2005-11-22 WO PCT/US2005/042700 patent/WO2007061415A1/fr not_active Ceased
- 2005-11-22 AU AU2005338461A patent/AU2005338461A1/en not_active Abandoned
2008
- 2008-02-19 IL IL189614A patent/IL189614A0/en unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9427402B2 (en)	2010-09-30	2016-08-30	Shionogi & Co. Ltd.	Preparation for improving solubility of poorly soluble drug

Also Published As

Publication number	Publication date
AU2005338461A1 (en)	2007-05-31
IL189614A0 (en)	2008-06-05
WO2007061415A1 (fr)	2007-05-31
CN101312714A (zh)	2008-11-26
JP2009515956A (ja)	2009-04-16

Legal Events

Date	Code	Title	Description
2008-03-18	EEER	Examination request
2012-10-01	FZDE	Discontinued
2012-12-24	FZDE	Discontinued	Effective date: 20121001

Publication	Publication Date	Title
US6517871B1 (en)	2003-02-11	Bioenhanced formulations comprising eprosartan in oral solid dosage form
TWI428333B (zh)	2014-03-01	醫藥組合物
JP4880591B2 (ja)	2012-02-22	イルベサルタンを含む医薬組成物
CA2623018A1 (fr)	2007-05-31	Compositions pharmaceutiques de telmisartan
CA2644179C (fr)	2018-09-25	Composition pharmaceutique inedite comprenant une matrice de desintegration
BRPI0716436B1 (pt)	2020-05-19	sistema de liberação controlada e método para fabricação do mesmo
KR20130091319A (ko)	2013-08-16	4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
CA2801020A1 (fr)	2011-12-01	Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide
HUP9902769A2 (hu)	2000-03-28	Eprosartan-dihidrát, valamint eljárás a vegyület előállítására és formálására
US10016374B2 (en)	2018-07-10	Disintegrant free composition of Cinacalcet
US20070116759A1 (en)	2007-05-24	Pharmaceutical compositions of telmisartan
US11576917B2 (en)	2023-02-14	Pharmaceutical compositions comprising Ibrutinib
US20090030057A1 (en)	2009-01-29	Pharmaceutical composition of telmisartan
JP7641098B2 (ja)	2025-03-06	リバーロキサバン含有錠剤
EP2638898A1 (fr)	2013-09-18	Formulation de pioglitazone et metformine avec différents profils de libération
PL384680A1 (pl)	2008-09-29	Kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz sposób jej wytwarzania
CN101090738A (zh)	2007-12-19	含有碱性药物或其盐的基质型缓释制剂及其制备方法
JP7511596B2 (ja)	2024-07-05	リバーロキサバン含有錠剤
EP2182927A2 (fr)	2010-05-12	Formulations améliorées de candesartan
US20150224086A1 (en)	2015-08-13	Pharmaceutical Formulations of Rufinamide
WO2007049291A1 (fr)	2007-05-03	Nouvelles formes solides de dosage de valsartan et d'hydrochlorothiazide
WO2022153330A1 (fr)	2022-07-21	Compositions pharmaceutiques comprenant de l'acalabrutinib
HK1103368A (en)	2007-12-21	Telmisartan-containing pharmaceutical compositions for oral intake
JP2021528381A (ja)	2021-10-21	ドーパミン−β−ヒドロキシラーゼ阻害剤を含む製剤及び該製剤の調製方法
WO2013098578A1 (fr)	2013-07-04	Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate

CA2623018A1 - Compositions pharmaceutiques de telmisartan - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=36645450

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (15)

Family Cites Families (2)

Cited By (1)

Also Published As

Similar Documents

Legal Events